title: Ending hepatitis C in the United States: the role of screening.
abstract: The US faces at least two distinct epidemics of hepatitis C virus infection (HCV), and due largely to revised screening recommendations and novel therapeutic agents, corresponding opportunities. As only 49%-75% of HCV-infected persons in the US are aware of their infection, any chance of addressing HCV in the US is dependent upon screening to identify undiagnosed infections. Most HCV in the US consists of longstanding infections among persons born during 1945-1965 who are suffering escalating rates of liver-related morbidity and mortality. Mathematical modeling supports aggressive action to reach and treat these persons to minimize the subsequent burden of advanced liver disease on patients and the health care system. Incident infection is primarily among persons who inject drugs, less than 10% of whom have been treated for HCV. Expanded screening and treatment of active persons who inject drugs raises the prospect of utilizing "treatment as prevention" to stem the tide of incident HCV infections in this population. HIV-positive men who have sex with men (MSM) represent a population at risk for sexually transmitted HCV who may also benefit from adjusted screening guidelines to identify both acute and chronic infections. Prisoners also represent a critical population for aggressive screening and treatment. Finally, the two-stage testing algorithm for HCV diagnosis is problematic and difficult for patients and providers to navigate. While emerging therapeutics raise the prospect of reducing HCV-related morbidity and mortality, as well as eliminating new infections, major barriers remain with regard to identifying infections, improving access to treatment, and ensuring payer coverage of costly new therapeutic regimens.
authors.affiliation: San Francisco Department of Public Health, Substance Use Research Unit, San Francisco, CA, USA.
authors.forename: Phillip O
authors.initials: PO
authors.lastname: Coffin
authors.affiliation: Project Inform, San Francisco, CA, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Reynolds
keywords: HCV screening; HCV treatment; treatment as prevention
references.citation: Harm Reduct J. 2013 Jun 20;10:10
references.pmid: 23786800
references.citation: Hepatology. 2014 May;59(5):1681-7
references.pmid: 24700278
references.citation: Clin Infect Dis. 2012 Jul;55 Suppl 1:S33-42
references.pmid: 22715212
references.citation: Lancet. 2014 Feb 8;383(9916):515-23
references.pmid: 24209977
references.citation: Lancet. 2013 Nov 9;382(9904):1564-74
references.pmid: 23993281
references.citation: Aliment Pharmacol Ther. 2013 Jul;38(2):124-33
references.pmid: 23725204
references.citation: J Viral Hepat. 2012 Dec;19(12):836-42
references.pmid: 23121361
references.citation: N Engl J Med. 2011 Jun 9;364(23):2199-207
references.pmid: 21631316
references.citation: J Gen Intern Med. 2005 Aug;20(8):754-8
references.pmid: 16050887
references.citation: Lancet. 2013 Nov 9;382(9904):1575-86
references.pmid: 23993280
references.citation: J Viral Hepat. 2006 Apr;13(4):264-71
references.pmid: 16611193
references.citation: Clin Infect Dis. 2007 Aug 15;45(4):e32-8
references.pmid: 17638183
references.citation: Public Health Rep. 2014 Mar-Apr;129(2):187-95
references.pmid: 24587554
references.citation: Am J Public Health. 2005 Oct;95(10):1739-40
references.pmid: 16186452
references.citation: J Infect Dis. 2011 Dec 15;204(12):1839-42
references.pmid: 22013222
references.citation: Public Health Rep. 2006 Nov-Dec;121(6):710-9
references.pmid: 17278406
references.citation: Clin Infect Dis. 2012 Jul;55(2):279-90
references.pmid: 22491339
references.citation: Clin Infect Dis. 2013 Jul;57(1):77-84
references.pmid: 23532480
references.citation: Hepatology. 2020 Feb;71(2):686-721
references.pmid: 31816111
references.citation: Clin Infect Dis. 2013 Aug;57 Suppl 2:S32-8
references.pmid: 23884063
references.citation: J Viral Hepat. 2013 Aug;20(8):550-5
references.pmid: 23808993
references.citation: Health Technol Assess. 2006 Sep;10(32):iii-iv, ix-xii, 1-93
references.pmid: 16948891
references.citation: Clin Infect Dis. 2010 Aug 1;51(3):267-73
references.pmid: 20575663
references.citation: Clin Infect Dis. 2009 Aug 15;49(4):561-73
references.pmid: 19589081
references.citation: J Urban Health. 2009 Jan;86(1):106-18
references.pmid: 18979201
references.citation: Am J Epidemiol. 2002 Apr 1;155(7):645-53
references.pmid: 11914192
references.citation: Drug Alcohol Depend. 2009 May 1;101(3):152-7
references.pmid: 19181458
references.citation: Clin Infect Dis. 2014 Mar;58(5):713-8
references.pmid: 24265358
references.citation: Sex Transm Dis. 2006 Apr;33(4):228-34
references.pmid: 16565643
references.citation: MMWR Morb Mortal Wkly Rep. 2011 Oct 28;60(42):1457-8
references.pmid: 22031220
references.citation: Am J Med. 2014 May;127(5):398-405
references.pmid: 24486288
references.citation: PLoS One. 2013;8(2):e54496
references.pmid: 23405084
references.citation: MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):357-61
references.pmid: 23657111
references.citation: Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6
references.pmid: 19861128
references.citation: Addiction. 2012 Jun;107(6):1057-65
references.pmid: 22168373
references.citation: Hepatology. 2012 Jan;55(1):49-57
references.pmid: 21898506
references.citation: J Infect Dis. 2014 Apr 15;209(8):1205-11
references.pmid: 24273176
references.citation: AIDS Patient Care STDS. 2011 Oct;25(10):571-7
references.pmid: 21859307
references.citation: Gastroenterol Clin Biol. 2009 Oct-Nov;33(10-11):977-80
references.pmid: 19765930
references.citation: Am J Med. 2001 Dec 1;111(8):614-21
references.pmid: 11755504
references.citation: Hepatology. 2013 Nov;58(5):1598-609
references.pmid: 23553643
references.citation: J Infect Dis. 2013 Jan 15;207(2):281-7
references.pmid: 23129759
references.citation: Clin Infect Dis. 2012 May;54(9):1259-71
references.pmid: 22412061
references.citation: Benefits Q. 2013;29(2):34-41
references.pmid: 23943955
references.citation: MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32
references.pmid: 22895429
references.citation: Ann Intern Med. 2012 Dec 4;157(11):817-22
references.pmid: 22910836
references.citation: J Infect Dis. 2013 Dec 15;208(12):1929-31
references.pmid: 24136791
references.citation: Ann Intern Med. 2012 Feb 21;156(4):263-70
references.pmid: 22056542
references.citation: Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S367-72
references.pmid: 15768350
references.citation: Prev Med. 2009 Aug;49(1):68-73
references.pmid: 19410600
references.citation: MMWR Morb Mortal Wkly Rep. 2011 Jul 22;60(28):945-50
references.pmid: 21775948
references.citation: Emerg Infect Dis. 2009 Sep;15(9):1499-502
references.pmid: 19788825
references.citation: Drug Alcohol Depend. 2013 Sep 1;132(1-2):53-62
references.pmid: 23357743
references.citation: J Viral Hepat. 2009 Nov;16(11):814-21
references.pmid: 19842281
references.citation: J Community Health. 2008 Jun;33(3):126-33
references.pmid: 18165889
references.citation: AIDS. 2011 Feb 20;25(4):399-409
references.pmid: 21139491
references.citation: J Clin Virol. 2011 Jun;51(2):105-9
references.pmid: 21507711
references.citation: Hepat Mon. 2013 Nov 05;13(11):e13593
references.pmid: 24348647
references.citation: Hepatology. 2013 Mar;57(3):944-52
references.pmid: 23111904
references.citation: Clin Infect Dis. 2013 Feb;56(3):405-13
references.pmid: 23090930
references.citation: Clin Infect Dis. 2014 Mar;58(6):755-61
references.pmid: 24363333
references.citation: Clin Infect Dis. 2012 Jul;55(1):137-44
references.pmid: 22534149
references.citation: Subst Abuse Rehabil. 2011 Oct;2(1):173-180
references.pmid: 23293547
references.citation: Ann Intern Med. 2002 Feb 19;136(4):288-92
references.pmid: 11848726